Answers are grounded in this paper and cite their sources.
Review evaluates bioequivalence and safety standards of generic ophthalmic medications, highlighting regulatory challenges in ensuring therapeutic equivalence.
The purpose of this review is to discuss the process of genericisation of medications in the US and Europe with a focus on ophthalmic drugs. Regulatory guidelines of the US Food and Drug Administration and the European Medicines Agency will be discussed, and the advantages and concerns of genericisation will be explored. We will look at various studies concerning the safety and efficacy of generic drugs compared to their branded counterparts. In particular, the challenges of assuring bioequivalence and therapeutic equivalence in topical ophthalmic drugs will be examined.
No takes yet. Share an insight, caveat, or question.
Zore et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: